Showing 1 - 8 results of 8 for search 'Anna Olsson-Brown', query time: 0.03s Refine Results
  1. 1
    A case of immunotherapy-induced thyroiditis

    A case of immunotherapy-induced thyroiditis by George Pears, Abhishek Mahajan, Anna Olsson-Brown, Joseph Sacco

    Published 2024-02-01
    Get full text
    Article
  2. 2
    Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction

    Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction by Anna Olsson-Brown, Rosemary Lord, Joseph Sacco, Jonathan Wagg, Mark Coles, Munir Pirmohamed

    Published 2020-04-01
    Get full text
    Article
  3. 3
    Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity

    Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity by Ik Shin Chin, Aman Khan, Anna Olsson-Brown, Sophie Papa, Gary Middleton, Claire Palles

    Published 2022-12-01
    Get full text
    Article
  4. 4
    Trabectedin Cardiotoxicity in Soft Tissue Sarcoma: A Case Series and Clinical Insights

    Trabectedin Cardiotoxicity in Soft Tissue Sarcoma: A Case Series and Clinical Insights by David G. Gent, Nasim Ali, Anna Olsson-Brown, Gregory Y.H. Lip, David J. Wright, Rebecca Dobson

    Published 2022-11-01
    Get full text
    Article
  5. 5
    Evolving cardiac biomarkers for immune checkpoint inhibitor related myocarditis in cancer patients

    Evolving cardiac biomarkers for immune checkpoint inhibitor related myocarditis in cancer patients by Suprateeka Talukder, Aruni Ghose, Turja Chakraborty, Anna Olsson-Brown, Sivatharshini Ramalingam, Stuart D. Rosen, Kate Young, Alexander R. Lyon, Arjun K. Ghosh

    Published 2023-12-01
    Get full text
    Article
  6. 6
    T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab

    T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab by Munir Pirmohamed, Anna Olsson-Brown, Lorenzo Ressel, Sean Hammond, Joshua Gardner, Serat-E Ali, Paul Thomson, Carol Jolly, Dan Carr, Dean Naisbitt

    Published 2021-05-01
    Get full text
    Article
  7. 7
    421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

    421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in pat... by Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Kevin Harrington, Robert Coffin, Howard Kaufman, Suzanne Thomas, Praveen Bommareddy, Francesca Aroldi, Pablo Nanclares, Lavita Menezes, Selda Samakoglu

    Published 2020-11-01
    Article
  8. 8
    507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors

    507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced s... by Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Kevin Harrington, Robert Coffin, Andrea Pirzkall, Praveen Bommareddy, Isla Leslie, Francesca Aroldi, Pablo Nenclares, Tze Chan, Imran Saleem, Henry Castro

    Published 2021-11-01
    Article

Search Tools: